EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?

Assunta Bianco iD, Gabriele Di Sante iD, Francesca Colò, Valeria De Arcangelis iD, Alessandra Cicia iD, Paola Del Giacomo, Maria De Bonis, Tommaso Giuseppe Morganti, Vincenzo Carlomagno iD, Matteo Lucchini iD, Angelo Minucci iD, Paolo Calabresi und 1 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25084556 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Assunta Bianco und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy. Hauptthemen laut MEDLINE: HLA-DRB1 Chains, COVID-19, Haplotypes, COVID-19 Vaccines. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A few cases of multiple sclerosis (MS) onset after COVID-19 vaccination have been reported, although the evidence is insufficient to establish causality. The aim of this study is to compare cases of newly diagnosed relapsing–remitting MS before and after the outbreak of the COVID-19 pandemic and the impact of COVID-19 vaccination. Potential environmental and genetic predisposing factors were also investigated, as well as clinical patterns. This is a single-centre retrospective cohort study including all patients who presented with relapsing–remitting MS onset between January 2018 and July 2022. Data on COVID-19 vaccination administration, dose, and type were collected. HLA-DRB1 genotyping was performed in three subgroups. A total of 266 patients received a new diagnosis of relapsing–remitting MS in our centre, 143 before the COVID-19 pandemic (until and including March 2020), and 123 during the COVID-19 era (from April 2020). The mean number of new MS onset cases per year was not different before and during the COVID-19 era and neither were baseline patients’ characteristics, type of onset, clinical recovery, or radiological patterns. Fourteen (11.4%) patients who subsequently received a new diagnosis of MS had a history of COVID-19 vaccination within one month before symptoms onset. Patients’ characteristics, type of onset, clinical recovery, and radiological patterns did not differ from those of patients with non-vaccine-related new diagnoses of MS. The allele frequencies of HLA-DRB1*15 were 17.6% and 22.2% in patients with non-vaccine-related disease onset before and during the COVID-19 era, respectively, while no case of HLA-DRB1*15 was identified among patients with a new diagnosis of MS post-COVID-19 vaccine. In contrast, HLA-DRB1*08+ or HLA-DRB1*10+ MS patients were present only in this subgroup. Although a causal link between COVID-19 vaccination and relapsing–remitting MS cannot be detected, it is interesting to note and speculate about the peculiarities and heterogeneities underlying disease mechanisms of MS, where the interactions of genetics and the environment could be crucial also for the follow-up and the evaluation of therapeutic options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HLA-DRB1 ChainsCOVID-19HaplotypesCOVID-19 VaccinesSARS-CoV-2HumansFemaleMaleAdultRetrospective StudiesMiddle AgedVaccinationMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisGenetic Predisposition to Disease

Stichwörter der Autor:innen

COVID-19 and autoimmune disordersHLA-DRB1 risk factorsSARS-CoV-2 vaccinationmultiple sclerosis

Substanzen

HLA-DRB1 ChainsCOVID-19 Vaccines

Autor:innen und Institutionen

  • Division of Neurology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
  • Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla "Anna Paola Batocchi", Catholic University of Sacred Heart, 00168 Rome, Italy.
  • Department of Medicine and Surgery, Section of Human, Clinical and Forensic Anatomy, University of Perugia, 06123 Perugia, Italy.
  • Department of Laboratory and Infectious Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
  • Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
  • Genomics Core Facility, Gemelli Science and Technology Park (G-STeP), Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.

ORCID-Profile: Assunta Bianco, Gabriele Di Sante, Valeria De Arcangelis, Alessandra Cicia, Vincenzo Carlomagno, Matteo Lucchini, Angelo Minucci, Massimiliano Mirabella

Zitieren

APA

Bianco, A., Di Sante, G., Colò, F., De Arcangelis, V., Cicia, A., Del Giacomo, P., De Bonis, M., Morganti, T. G., Carlomagno, V., Lucchini, M., Minucci, A., Calabresi, P., & Mirabella, M. (2024). Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084556

Vancouver

Bianco A, Di Sante G, Colò F, De Arcangelis V, Cicia A, Del Giacomo P, et al. Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25084556

BibTeX
@article{Bianco2024,
  author = {Bianco, Assunta and Di Sante, Gabriele and Colò, Francesca and De Arcangelis, Valeria and Cicia, Alessandra and Del Giacomo, Paola and De Bonis, Maria and Morganti, Tommaso Giuseppe and Carlomagno, Vincenzo and Lucchini, Matteo and Minucci, Angelo and Calabresi, Paolo and Mirabella, Massimiliano},
  title = {Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25084556}
}
Kostenlos starten →